(TheNewswire)
Kelowna, British Columbia – April22, 2025 – TheNewswire- Rize Oncology Inc. RIZE (“Rize” or
the “Company”), a clinical-stage pharmaceutical company focused on
developing innovative oncology therapeutics, today announced that its
Board of Directors has authorized the Company to seek shareholder
approval for the voluntary delisting of its common shares from the
Canadian Securities Exchange (“CSE”).
The proposed delisting is subject to the approval of amajority of the Company’s shareholders, excluding votes cast by“Related Persons” (as defined in CSE Policy 1), and final approvalby the CSE. In accordance with CSE Policies, Rize anticipates seekingthe requisite shareholder approval via written resolution signed byholders of more than 50% of the common shares eligible to vote on theresolution. If such approvals are obtained, Rize intends to proceedwith the delisting of its common shares from the CSE…
